Dipankar Bhattacharya
Overview
Explore the profile of Dipankar Bhattacharya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma F, Longo M, Meroni M, Bhattacharya D, Paolini E, Mughal S, et al.
Cell Metab
. 2025 Feb;
PMID: 40015280
Excess cholesterol accumulation contributes to fibrogenesis in metabolic dysfunction-associated steatohepatitis (MASH), but how hepatic cholesterol metabolism becomes dysregulated in MASH is not completely understood. We show that human fibrotic MASH...
2.
Prasad K, Bhattacharya D, Eldin Shams S, Izarraras K, Hart T, Mayfield B, et al.
Cells
. 2024 Oct;
13(19.
PMID: 39404414
The peptide hormone kisspeptin attenuates liver steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and fibrosis in mouse models by signaling via the kisspeptin 1 receptor (KISS1R). However, whether kisspeptin impacts fibrogenesis in...
3.
Vacca M, Kamzolas I, Harder L, Oakley F, Trautwein C, Hatting M, et al.
Nat Metab
. 2024 Jun;
6(6):1178-1196.
PMID: 38867022
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is...
4.
Yashaswini C, Qin T, Bhattacharya D, Amor C, Lowe S, Lujambio A, et al.
J Hepatol
. 2024 Mar;
81(2):207-217.
PMID: 38508241
Background & Aims: Hepatic stellate cells (HSCs) are the key drivers of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), the fastest growing cause of hepatocellular carcinoma (HCC) worldwide. HSCs are heterogenous,...
5.
Li X, Bhattacharya D, Yuan Y, Wei C, Zhong F, Ding F, et al.
Kidney Int
. 2023 Dec;
105(3):540-561.
PMID: 38159678
Clinical studies suggest that non-alcoholic steatohepatitis (NASH) is an independent risk factor for chronic kidney disease (CKD), but causality and mechanisms linking these two major diseases are lacking. To assess...
6.
Wang S, Li K, Pickholz E, Dobie R, Matchett K, Henderson N, et al.
Sci Transl Med
. 2023 Jan;
15(677):eadd3949.
PMID: 36599008
Advanced hepatic fibrosis, driven by the activation of hepatic stellate cells (HSCs), affects millions worldwide and is the strongest predictor of mortality in nonalcoholic steatohepatitis (NASH); however, there are no...
7.
OFarrell M, Duke G, Crowley R, Buckley D, Martins E, Bhattacharya D, et al.
Sci Rep
. 2022 Sep;
12(1):15661.
PMID: 36123383
Fatty acid synthase (FASN) is an attractive therapeutic target in non-alcoholic steatohepatitis (NASH) because it drives de novo lipogenesis and mediates pro-inflammatory and fibrogenic signaling. We therefore tested pharmacological inhibition...
8.
Kennedy P, Stocker D, Carbonell G, Said D, Bane O, Hectors S, et al.
Eur Radiol
. 2022 Jun;
32(12):8339-8349.
PMID: 35727321
Objectives: Portal hypertension (PH) is associated with complications such as ascites and esophageal varices and is typically diagnosed through invasive hepatic venous pressure gradient (HVPG) measurement, which is not widely...
9.
Bhattacharya D, Becker C, Readhead B, Goossens N, Novik J, Fiel M, et al.
Sci Rep
. 2021 Oct;
11(1):20827.
PMID: 34675338
Non-alcoholic steatohepatitis (NASH) is a rising health challenge, with no approved drugs. We used a computational drug repositioning strategy to uncover a novel therapy for NASH, identifying a GABA-B receptor...
10.
Ranea-Robles P, Chen H, Stauffer B, Yu C, Bhattacharya D, Friedman S, et al.
J Inherit Metab Dis
. 2021 Sep;
44(6):1419-1433.
PMID: 34564857
Peroxisomes metabolize a specific subset of fatty acids, which include dicarboxylic fatty acids (DCAs) generated by ω-oxidation. Data obtained in vitro suggest that the peroxisomal transporter ABCD3 (also known as...